AnaptysBio price target raised to $59 from $38 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on AnaptysBio (ANAB) to $59 from $38 and keeps a Buy rating on the shares after the company announced it is planning to separate its biopharma operations and its established royalty revenue business into two separately traded public companies. The firm upped the price target after fully modeling out expected royalties and market models for Jemperli and imsidolimab.